CSN Login
Members Online: 12

You are here

RAS mutation may be even more important than determining treatment options, according to MDAnderson study

coloCan
Posts: 1920
Joined: Oct 2009

www.mdanderson.org/publications/oncolog/ras-mutation-status-may-predict-outcomes-after-surgery-for-colorectal-cancer-liver-metastases-oncol

Direct link doesn't seem to work,but if you type in "ras mutation" in search box of page that appears, you'll get this interesting article,if so interested (key word:"MAY")

(something calledCH4987655 (Ro4987655) is a MEK inhibitor that may prove useful with Ras/Raf mutations,tho in early phase trial 

Also,MGD007 is starting to enroll people for trial......and its not named for James Bonds' unknown cousin)

 

 

coloCan
Posts: 1920
Joined: Oct 2009

a company named Xbiotech is starting to enroll people in a phase III study of something called "Xilonix"....FYI

(again,FDA may be fast-tracking MGD007)

 

coloCan
Posts: 1920
Joined: Oct 2009

Sym004...................

and here's something someone may find of interest onKRAS/NRAS mutations(interesting site too)

www.mycancergenome.org/content/disease/colorectal-cancer/nras/316

PS:Just came across this,a combo of cetuximab and trastuzumab

http://onlinelibrary.wiley.com/doi/10.1111/cpr.12125/abstract

 

 

Quick2Listen
Posts: 1
Joined: Jun 2014

Although there are many genetic mutations classified as Kras + Tumors with mutated KRAS genes do not respond to treatment with cetuximab or panitumumab as yet

 

coloCan
Posts: 1920
Joined: Oct 2009

Supposedly good results thus far for Xilonix

www.sys-con.com/node/3168361

and phaae III starting for MGN 1703 (tho i think in Germany now)

also,good news from phase iii on Ramucirumab........

Subscribe to Comments for "RAS mutation may be even  more important than determining treatment options, according to MDAnderson study"